MiNK Therapeutics invests in B. Riley Securities Oncology…
NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc.a clinical-stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural